Astellas, Poseida partner to develop allogeneic cell therapies for cancer
Poseida will combine its unique allogeneic CAR-T platform with Xyphos' ACCELTM technology to create one Poseida-developed CAR-T construct,…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
02 May 24
Poseida will combine its unique allogeneic CAR-T platform with Xyphos' ACCELTM technology to create one Poseida-developed CAR-T construct,…
02 May 24
The high-concentration, citrate-free formulation of Cyltezo injection is now authorised in the US to treat multiple chronic inflammatory…
02 May 24
The CardiAMP Cell Therapy increased the exercise tolerance by 107-second and reduced angina episodes by 82% at the…
02 May 24
As per the partnership, Nasdaq-listed Editas Medicine and Bristol Myers Squibb will research, develop, and market T cell…
02 May 24
A new study published in Diagnostic Microbiology & Infectious Disease shows that Copan’s Colibrí™ instrument accurately automates sample preparation…
01 May 24
Bayer and Evotec are expanding their collaboration to develop innovative therapies in precision cardiology, and the strategic alliance…
01 May 24
The positive top-line results revealed that the Phase 2/3 trial achieved its primary endpoint of improvement on the…
01 May 24
Lupkynis’ updated label no longer includes the disclaimer regarding its safety and efficacy beyond one year and incorporates…
01 May 24
The partnership, spread across various therapeutic fields, aims to assess the use of polygenic risk scores in improving…
30 Apr 24
ONO will merge Deciphera with and into its fully owned subsidiary, with Deciphera as the surviving entity, which…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates